EQ (Equillium) Growth Rank: 0 (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EQ Equillium Inc EQ
34 GF Score
Price $2.21
GF Value $0.10
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Equillium Growth Rank?

Equillium has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

EQ
34GF Score
Equillium Inc EQ
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Equillium (EQ) Overvalued in 2026?

Based on GuruFocus' analysis, Equillium stock appears to be overvalued. The current stock price of $2.21 is trading 2110% above its estimated GF Value™ of $0.10. GuruFocus considers Equillium to be Significantly Overvalued.

Key valuation signals for EQ:

  • Growth Rank: 0
  • GF Value™: $0.10 vs. price of $2.21 (2110% above fair value)
  • GF Score™: 34/100 with 1 warning sign

No single metric tells the full story. See the EQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equillium Business Description

Other Exchanges 0A4D:UK0FY:Germany
Address 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
34GF Score

Get the complete analysis for EQ

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.21
Price
$0.10
GF Value